Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Liraglutide · 1 trial · 1 indication
The mean energy intake was collected to assess the effect of liraglutide on food intake in non-diabetic, obese participants. Observed food intake was measured as the total number of calories consumed during the specified time period, calculated as the difference of the total number of calories provided minus the total number of calories remaining after meals. Mean energy intakes at Visit 4 was defined as the mean values of the measurements at Study Day 20 and 21. Same definition applies to Visit 5 (Study Day 41 and 42). Baseline was defined as the mean of Visit 3 (Study Day -1 and 0).
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | Liraglutide |
| Placebo | PLACEBO_COMPARATOR | Placebo comparator |
| Name | Type | Description |
|---|---|---|
| Liraglutide | DRUG | Liraglutide |
| Placebo | OTHER | Placebo |
Inclusion Criteria: * Males and female subjects; * Body Mass Index 30-40 kg/m2; Exclusion Criteria: * Evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug a...
Top 20 of 32 competitors
Liraglutide is being studied for the treatment of obesity. It is an investigational small molecule in Phase 1 clinical development. A completed Phase 1 trial examined its effects on food intake in obese subjects over a 6-week period.
Liraglutide is being developed by Pfizer, Inc., which is listed on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical research to evaluate the drug's potential in treating obesity.
Liraglutide is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and the drug is not yet available for clinical use.
Liraglutide has one completed Phase 1 trial, identified as NCT03041792, titled "Methodology Study To Examine 6-Week Food Intake With Liraglutide In Obese Subjects." This randomized, double-blind, placebo-controlled study enrolled 61 participants in the United States.
Liraglutide is not FDA approved for obesity. It is an investigational drug currently in Phase 1 clinical development. The completed Phase 1 trial was a methodology study, and further clinical trials would be needed before any regulatory approval could be considered.